Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Ocular Therapeutix (OCUL) · oqro.io/stocks/OCUL · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Ocular Therapeutix insider trading
Have Ocular Therapeutix insiders bought shares recently?
No open-market purchase by an insider of Ocular Therapeutix was filed in the last 90 days. The latest on record was on May 13, 2025.
How often do Ocular Therapeutix insiders buy and sell shares?
Since 2014, Ocular Therapeutix insiders reported 73 open-market purchases and 62 sales on Forms 4 and 5, with purchases in 12 different years, most recently 2025.
Who is selling Ocular Therapeutix stock?
In the last 90 days, 4 insiders of Ocular Therapeutix (OCUL) reported 4 open-market sales worth $466K in total on SEC Form 4. The largest seller by value was Namrata Saroj, with $232K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade OCUL?
No trade in Ocular Therapeutix (OCUL) was disclosed by a member of Congress in the last 12 months.
When does Ocular Therapeutix report its next results?
Ocular Therapeutix's next results are expected on Feb 3, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−52.5% (−$6.15) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $11.72 on Nov 20, 2025 to $5.57 on Nov 20, 2026 (−52.5%). Disclosed in this range: 0 insider trades, 4 pre-arranged insider sales, 0 Congress trades, and 7 13F position changes for 3 quarters ending in it.
$0$10$15$20$5.57
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 4 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Bedford, Ma.
Last 12 months
−52.5%
S&P 500 +5.7% over the same dates
Market value
$1.32B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 29M shares sold short (12.2% of shares outstanding), +0.8% vs the previous count, 10.1 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insider buying and selling since 2014
Insiders of Ocular Therapeutix reported 73 open-market purchases and 62 sales since 2014; purchases in 12 different years, most recently 2025.
Year
Bought
Sold
2026
—
$466K4×4 trades
2025
$70K1×1 trade
$1.03M16×16 trades
2024
$7M1×1 trade
$1.03M18×18 trades
2023
$5.02M2×2 trades
$193K6×6 trades
2022
$1.82M17×17 trades
—
2021
$976K7×7 trades
$143K1×1 trade
2020
$8.71M11×11 trades
—1×1 trade
2019
$1.13M13×13 trades
—
2018
$514K6×6 trades
—
2017
$305K4×4 trades
—
2016
$423K2×2 trades
—
2015
$330K3×3 trades
$64.2M16×16 trades
2014
$9.21M6×6 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last 30 days
Written by software from the filings listed below · Oct 26, 2026
Insiders.Ocular Therapeutix on OQRO: In the 30 days to Oct 26, 2026, insiders filed 0 open-market purchases and 3 open-market sales (about $234K, in 3 filings, by 3 people). The largest sale was by Todd Anderman, Chief Legal Officer, about $87K, filed Oct 13, 2026.
3 more points, with the facts they come from, are in OQRO Pro.
On the public record for Ocular Therapeutix over the 12 months to Nov 18, 2026: 2 clinical trials.
Red flags in its filings
Oct 16
Top officer leaving
“(the “Company”), notified the Company of his resignation from the Company, effective October 16, 2026, to become the Chief Executive Officer of a privately-held company.”
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Owners above 5%
No Schedule 13D or 13G filing on OCUL over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Ocular Therapeutix filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 4 open-market sales (about $466K, in 4 filings, by 4 people). One Form 4 can list many transactions. In the 12 months before that, they filed 1 open-market purchase (about $70K, in 1 filing) and 20 open-market sales (about $1.28M, in 19 filings). (Ocular Therapeutix on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 4 new or larger positions and 3 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. ClinicalTrials.gov shows 2 studys sponsored by the company updated in the period; the latest, "Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascula..." (Phase 3, status recruiting), was updated on Jul 1, 2026, with primary completion listed for 2030-08-01. FINRA short interest for OCUL on the settlement date of Oct 30, 2026 was 28,998,345 shares (+0.83% on the previous report), about 10.14 days of average volume.
Company reports, price and press. Ocular Therapeutix filed a Form 8-K on Nov 9, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member. Ocular Therapeutix filed a Form 8-K on Oct 16, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
Who holds it. 261 funds reported a stake in Ocular Therapeutix in their 13F for Q2 2026. The largest by value: FMR LLC (15.8% of the value reported), Deep Track Capital, LP (9.5% of the value reported), BlackRock, Inc. (9.3% of the value reported).
Latest results: quarter ending Sep 30, 2026
Revenue
$12.9M
−11.5% vs the same quarter a year earlier
Free cash flow, last 12 months
−$267M
This quarter −$68.7M, a year earlier −$56.7M
Net debt
—
Debt —, cash $531M, at Sep 30, 2026
Net income, last 12 months
−$327M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 9, 2026.
after the market closes; the date can move until the company confirms it
Purchases after results
54%
36 of 67 insider purchases since 2014 came within 30 days after a results announcement
From Ocular Therapeutix's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Ocular Therapeutix's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Ocular Therapeutix filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 4 open-market sales (about $466K, in 4 filings, by 4 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 1 open-market purchase (about $70K, in 1 filing) and 20 open-market sales (about $1.28M, in 19 filings).
The largest sale: Namrata Saroj, Chief Business Officer, about $232K, filed Nov 9, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 4 new or larger positions and 3 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
ClinicalTrials.gov shows 2 studys sponsored by the company updated in the period; the latest, "Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascula..." (Phase 3, status recruiting), was updated on Jul 1, 2026, with primary completion listed for 2030-08-01.
FINRA short interest for OCUL on the settlement date of Oct 30, 2026 was 28,998,345 shares (+0.83% on the previous report), about 10.14 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Avoro Capital Advisors LLC (increased, 225,000 shares); Orbimed Advisors LLC (new position); the largest that shrank: Artisan Partners Limited Partnership (sold out); Perceptive Advisors LLC (sold out). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $35.9M for its principal executive officer, and an average of $3.52M for the other named executive officers.
Company reports, price and press
Ocular Therapeutix filed a Form 8-K on Nov 9, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
Ocular Therapeutix filed a Form 8-K on Oct 16, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph.D., Chief Strategy Officer of Ocular Therapeutix, Inc. (the 'Company'), notified the Company of his resignation from the Company, effective October 16, 2026, to become the Chief Exe..."
Ocular Therapeutix filed a Form 8-K on Jun 12, 2026 (Items 5.02, 5.07) that OQRO classes as: changed a top executive or board member, and held a shareholder vote.
The company's own opening sentence of that report reads: "On June 10, 2026, Ocular Therapeutix, Inc. (the 'Company') held its 2026 Annual Meeting of Stockholders (the '2026 Annual Meeting'). At the 2026 Annual Meeting, the Company’s stockholders approved an amendment ('Amendment No. 5')..."
Press coverage listed by Finnhub: "Ocular Therapeutix, Inc. Q3 2026 Earnings Call Summary" (Yahoo, Nov 9, 2026).
Press coverage listed by Finnhub: "Ocular Therapeutix falls on third quarter earnings miss" (Yahoo, Nov 9, 2026).
Press coverage listed by Finnhub: "Ocular Therapeutix: Q3 Earnings Snapshot" (Yahoo, Nov 9, 2026).
OCUL closed at $5.94 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $6.29 to $5.94, a change of −5.6%.
Who holds it
261 funds reported a stake in Ocular Therapeutix in their 13F for Q2 2026. The largest by value: FMR LLC (15.8% of the value reported), Deep Track Capital, LP (9.5% of the value reported), BlackRock, Inc. (9.3% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Since Nov 18, 2025, OCUL is down 52.6% and the index fund is up 4.5%: 57 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much OCUL moves
A usual day
±2.4%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
7.8%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−21.3%Feb 17, 2026
Largest one-day rise
+28.1%Dec 8, 2025
Deepest fall of the year
−65.4%From the close of Dec 8, 2025 to Nov 20, 2026.
Days of 5% or more
48Out of 252 sessions, in either direction.
Beta 1.4(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
Off-exchange trading: 45.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (20.6% on ATS, 24.4% with other brokers), above its 26-week average of 42.1%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: INTELLIGENT CROSS LLC (15.0%), MS TRAJECTORY CROSS (ATS-1) (9.7%), UBS ATS (9.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
1 certified in FY2026 Q3, vs 4 a year earlier. 1 position in total, median offered wage $135K a year.
Senior Computer Systems Validation Engineer · 1
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Late-stage clinical trials
4 active phase 3 trials and 0 active phase 2 trials led by this company, mostly in neovascular age-related macular degeneration, neovascular age-related macular degeneration, non-proliferative diabetic retinopathy. The ones with the nearest registered primary completion date still ahead:
1 trial has a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Where the revenue comes from
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 5, 2026. Read the filing
By product or service
Product revenue, net$51.8M100%
−18% on the year before ($63.5M)
Collaboration revenue$128K0.2%
−51% on the year before ($262K)
Total revenue$52M−18%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 11,000 words.
From “Our Company”, in the company's words
on our ELUTYX proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently being evaluated in a Phase 3 registrational program for wet age-related macular degeneration, or wet AMD, which we refer to as the SOL program. AXPAXLI is currently also being evaluated in a Phase 3 registrational program for diabetic retinal disease, including non-proliferative diabetic retinopathy, or NPDR, which we refer to as the HELIOS program. We also leverage the ELUTYX technology in our commercial product DEXTENZA, a corticosteroid approved by the U.S.
What the section covers (32 headings)
Overview
Our Company
Key Business and Financial Developments
AXPAXLI for the treatment of wet AMD
AXPAXLI for the treatment of diabetic retinal disease
OTX-TIC for OAG or OHT
2025 Offering
Commercial
Other Developments
Components of our Financial Performance
Revenue
Operating Expenses
Cost of Product Revenue
Research and Development Expenses
And 18 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 5, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Risk factors in the annual report
Latest annual report filed Feb 5, 2026, compared with the one filed Mar 3, 2025. Read the filing
New risk factors in the latest annual report (3 headings)
Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition.
Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development programs and develop and secure approval of our product candidates in a timely manner, which would negatively impact our business.
Changes in and uncertainty surrounding U.S. and international trade policies may adversely impact our business and operating results.
No longer listed (2 headings from the year before)
If we are not able to obtain patent term extensions in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for our product and product candidates, our business may be impaired.
Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies’ operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
Legal proceedings (Item 3)
From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not presently a party to any material legal proceedings, nor to the knowledge of management are any material legal proceedings threatened against us.
Source: SEC EDGAR, Form 10-K filed Feb 5, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.